Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of 2-Picolinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 2/20 | 0.45 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.64 |
| ▸ | CES1 | P23141 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.61 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | GSK3B | P49841 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2-Picolinic Acid SCHEMBL29357933 | 1.00 | CES2 (0.64) | CES2CES1L3MBTL1LMNAP4HTM | |
| 2-Picolinic Acid SCHEMBL29897322 | 1.00 | CES2 (0.64) | CES2CES1L3MBTL1LMNAP4HTM | |
| 2-Picolinic Acid SCHEMBL30616634 | 0.98 | CES2 (0.61) | CES2CES1L3MBTL1LMNAP4HTM | |
| 2-Picolinic Acid SCHEMBL11280519 | 0.98 | CES2 (0.61) | CES2CES1L3MBTL1LMNAP4HTM | |
| 2-Picolinic Acid SCHEMBL11378795 | 0.98 | CES2 (0.67) | CES2CES1L3MBTL1LMNAP4HTM | |
| 2-Picolinic Acid SCHEMBL5058098 | 0.95 | CES2 (0.64) | CES2CES1L3MBTL1LMNAP4HTM | |
| 2-Picolinic Acid SCHEMBL524041 | 0.95 | CES2 (0.64) | CES2CES1L3MBTL1LMNAP4HTM | |
| 2-Picolinic Acid SCHEMBL15401421 | 0.95 | CES2 (0.64) | CES2CES1L3MBTL1LMNAP4HTM | |
| 2-Picolinic Acid SCHEMBL673572 | 0.95 | CES2 (0.64) | CES2CES1L3MBTL1LMNAP4HTM | |
| 2-Picolinic Acid SCHEMBL5354659 | 0.95 | CES2 (0.64) | CES2CES1L3MBTL1LMNAP4HTM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 578 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12268676-B2 | Antiviral applications of picolinic acid and its derivatives | INDIAN INSTITUTE OF SCIENCE (IN) | 2025-04-08 | — | — | US | claimed |
| CN-119632935-A | Anti-aging and body-strengthening and age-prolonging pill and preparation method thereof | 江西大自然制药有限公司 | 2025-03-18 | — | — | CN | claimed |
| US-20240342147-A1 | MAGNESIUM PICOLINATE COMPOSITIONS AND METHODS OF USE | BONAFIDE HEALTH LLC (US) | 2024-10-17 | — | — | US | claimed |
| CN-117105834-A | Modified D101 resin catalysis H 2 S method for preparing thioamides | 南京大学 | 2023-11-24 | — | — | CN | claimed |
| CN-116947746-A | Preparation method of sodium picosulfate | 山东创新药物研发有限公司 | 2023-10-27 | — | — | CN | claimed |
| CN-116539389-A | Water-soluble trace element tracer and preparation method and application thereof | 大庆信辰油田技术服务有限公司 | 2023-08-04 | — | — | CN | claimed |
| CN-109251168-B | Method for preparing pyridine-2-formic acid by using 2-OP rectification residues | 盐城工学院 | 2022-10-18 | — | — | CN | claimed |
| CN-109251169-B | Method for preparing pyridine-2-chromium formate by using 2-OP rectification residue | 盐城工学院 | 2022-08-16 | — | — | CN | claimed |
| WO-2022157656-A1 | ANTIVIRAL APPLICATIONS OF PICOLINIC ACID AND ITS DERIVATIVES | INDIAN INSTITUTE OF SCIENCE (IN) | 2022-07-28 | — | — | WO | claimed |
| US-20220226292-A1 | Antiviral Applications of Picolinic Acid and its Derivatives | INDIAN INSTITUTE OF SCIENCE (IN) | 2022-07-21 | — | — | US | claimed |
| EP-1361865-A2 | CUBIC LIQUID CRYSTALLINE COMPOSITIONS AND METHODS FOR THEIR PREPARATION | THE PROCTER & GAMBLE COMPANY (US) | 2003-11-19 | — | — | EP | claimed |
| US-20020160040-A1 | Cubic liquid crystalline compositions and methods for their preparation | CHILDREN'S HOSPITAL RESEARCH FOUNDATION | 2002-10-31 | — | — | US | claimed |
| WO-2002066014-A2 | CUBIC LIQUID CRYSTALLINE COMPOSITIONS AND METHODS FOR THEIR PREPARATION | THE PROCTER & GAMBLE COMPANY (US) | 2002-08-29 | — | — | WO | claimed |
| US-20020048551-A1 | Delivery of biologically active material in a liposomal formulation for administration into the mouth | KELLER BRIAN C (US) | 2002-04-25 | — | — | US | claimed |
| EP-0928189-A4 | DELIVERY OF BIOLOGICALLY ACTIVE MATERIAL IN A LIPOSOMAL FORMULATION FOR ADMINISTRATION INTO THE MOUTH | BIOZONE LAB INC (US) | 2001-03-28 | — | — | EP | claimed |
| EP-0928189-A1 | DELIVERY OF BIOLOGICALLY ACTIVE MATERIAL IN A LIPOSOMAL FORMULATION FOR ADMINISTRATION INTO THE MOUTH | Biozone Laboratories, Inc. (US) | 1999-07-14 | — | — | EP | claimed |
| WO-1997042938-A1 | DELIVERY OF BIOLOGICALLY ACTIVE MATERIAL IN A LIPOSOMAL FORMULATION FOR ADMINISTRATION INTO THE MOUTH | BIOZONE LABORATORIES, INC. (US) | 1997-11-20 | — | — | WO | claimed |
| EP-0272903-B1 | PROCESS FOR PRODUCING A POLYARYLENE SULFIDE | Tosoh Corporation (JP) | 1993-07-21 | — | — | EP | claimed |
| US-4794163-A | HIGH MOLECULAR WEIGHT, HEAT RESISTANCE | TOSOH CORPORATION (JP) | 1988-12-27 | — | — | US | claimed |
| EP-0272903-A2 | Process for producing a polyarylene sulfide | Tosoh Corporation (JP) | 1988-06-29 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240342147-A1 | MAGNESIUM PICOLINATE COMPOSITIONS AND METHODS OF USE | PLPBP, CYP27B1, SLC39A7 | PTGS2 336/4885PTGS1 267/4885CES2 2755/4885 |
| US-20020160040-A1 | Cubic liquid crystalline compositions and methods for their preparation | SKP1, CCNB1, CRYAA | PTGS2 3872/4885PTGS1 3275/4885CES2 3093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.